Nanohale AG (ETR:FYB) | Finanzwire

Basculer en Français

9529	Companies
187479	Keywords
119514	Articles
100217	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 12/09/2025 at 13:09, 6 days 6 hours ago

Formycon and Zydus Forge Licensing Agreement for FYB206 in North America

Licensing Agreement Biosimilar Formycon Keytruda Zydus
PRESS RELEASE

published on 12/09/2025 at 13:04, 6 days 6 hours ago

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
Formycon AG and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada. Agreement includes milestone payments, development progress, and upcoming data release

Formycon AG Biosimilar Keytruda Zydus Exclusive Licensing
BRIEF

published on 12/04/2025 at 06:35, 11 days 12 hours ago

Formycon and MS Pharma Collaborate for Keytruda® Biosimilar in MENA

MS Pharma Biosimilar Agreement Keytruda® FYB206 MENA Market Formycon Partnership
PRESS RELEASE

published on 12/04/2025 at 06:30, 11 days 12 hours ago

Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
Formycon AG and MS Pharma enter exclusive partnership to commercialize Keytruda biosimilar FYB206 in MENA region, aiming to enhance cancer drug access

MENA Region MS Pharma Biosimilar Formycon Keytruda
BRIEF

published on 11/24/2025 at 06:35, 21 days 12 hours ago

Formycon Partners with NTC for Biosimilar Commercialization in Italy

Formycon AG Ophthalmology Biosimilar Partnerships Italy Pharmaceutical Market FYB203/Baiama®
PRESS RELEASE

published on 11/24/2025 at 06:30, 21 days 12 hours ago

NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy
Formycon AG partners with NTC for Eylea biosimilar commercialization in Italy. Agreement includes royalties and supply chain organization

Italy Formycon AG Commercialization Eylea Biosimilar NTC
BRIEF

published on 11/20/2025 at 17:05, 25 days 2 hours ago

First Berlin Reaffirms Buy Rating for Formycon AG

BUY Rating Formycon AG Revenue Guidance Dupixent Keytruda Biosimilar
PRESS RELEASE

published on 11/20/2025 at 17:00, 25 days 2 hours ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Buy recommendation on Formycon AG (DE000A1EWVY8) to EUR 53 target price post Q3 results surpassing expectations and upcoming FYB206 study endpoint results

First Berlin Equity Research Buy Recommendation Formycon AG FYB206 EUR 53 Target Price
BRIEF

published on 11/20/2025 at 06:35, 25 days 12 hours ago

Ranibizumab Biosimilar Epruvy® Launched in Germany

Formycon AG Ranibizumab Biosimilar Germany Launch Ophthalmic Care
PRESS RELEASE

published on 11/20/2025 at 06:30, 25 days 12 hours ago

Ranibizumab Biosimilar Epruvy® launched in Germany
Ranibizumab Biosimilar Epruvy® launched in Germany by Formycon AG, Bioeq AG, and Sandoz AG under license agreement, expanding patient access to treatment options for nAMD and retinopathies

Formycon AG Germany Ranibizumab Sandoz AG Epruvy

Accesswire

Published on 12/15/2025 at 18:15, 56 minutes ago

Athena Gold Closes Second Tranche of Non-brokered Private Placement and Increases Offering Due to Strong Demand
Published on 12/15/2025 at 16:35, 2 hours 36 minutes ago

Stillwater Critical Minerals Announces Upsize of Bought Deal LIFE Private Placement for Gross Proceeds of C$15 Million
Published on 12/15/2025 at 15:00, 4 hours 11 minutes ago

Kingfisher Reports Annual General Meeting Voting Results
Published on 12/15/2025 at 15:00, 4 hours 11 minutes ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Published on 12/15/2025 at 14:30, 4 hours 41 minutes ago

Unusual Machines Congratulates Customers Selected for the Army's PBAS Tranche 1.1, Including Envision Technology and Strategic Logix

View all ACCESSWIRE

EQS Group

Published on 12/15/2025 at 18:15, 56 minutes ago

Results of EQT’s mandatory simplified cash tender offer for Waga Energy’s remaining shares
Published on 12/15/2025 at 18:07, 1 hour 3 minutes ago

POS-Transaction in Own Shares
Published on 12/15/2025 at 18:00, 1 hour 11 minutes ago

LIGHTON: Adjustment of ARR target for FY 2025
Published on 12/15/2025 at 17:45, 1 hour 26 minutes ago

EQS-Adhoc: Airbus SE: Airbus reports share buybacks for week starting 8 December 2025
Published on 12/15/2025 at 17:38, 1 hour 32 minutes ago

Stabilus SE approves share buyback program with a volume of up to €20 million

Les Echos

Published on 12/15/2025 at 18:30, 41 minutes ago

MCH PRIVATE EQUITY AND EURAZEO ENTER INTO AN EXCLUSIVE AGREEMENT WITH ARDIAN FOR THE SALE OF THEIR MAJORITY STAKE IN FERMAX
Published on 12/15/2025 at 18:05, 1 hour 6 minutes ago

Covivio - Treasury shares transactions between December 8th , 2025 and December 12th, 2025
Published on 12/15/2025 at 17:45, 1 hour 25 minutes ago

ENGIE strengthens the resilience of the Belgian electricity system with new flexible capacities
Published on 12/15/2025 at 17:40, 1 hour 31 minutes ago

LISI joins the SBF 120 and CAC Mid 60 indices
Published on 12/15/2025 at 17:35, 1 hour 36 minutes ago

DISCLOSURE OF TRANSACTIONS IN OWN SHARES FROM DECEMBER 8 TO DECEMBER 12, 2025

View all LES ECHOS COMFI WIRE